BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy

被引:19
|
作者
Koetz, Kathrin R. [1 ]
van Rossum, Elisabeth F. C. [2 ]
Ventz, Manfred [1 ]
Diederich, Sven [3 ]
Quinkler, Marcus [1 ]
机构
[1] Charite, Charite Campus Mitte, Dept Clin Endocrinol, D-10117 Berlin, Germany
[2] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
[3] Endokrinologikum, Berlin, Germany
关键词
QUALITY-OF-LIFE; ADRENAL INSUFFICIENCY; ADDISONS-DISEASE; ORAL CORTICOSTEROIDS; INCREASED RISK; SENSITIVITY; FRACTURES; QUESTIONNAIRE; MANAGEMENT;
D O I
10.1111/cen.12096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Patients with primary adrenal insufficiency (PAI) and patients with congenital adrenal hyperplasia (CAH) receive weight-adapted standard glucocorticoid replacement therapy. Clinically, some patients appear more sensitive to therapeutic administration of glucocorticoids than others. Glucocorticoid sensitivity is at least partially genetically determined by polymorphisms of the glucocorticoid receptor (GR) and might influence bone mineral density (BMD). Objectives To determine if bone turnover markers and BMD are associated with the GR gene polymorphism BclI in patients with PAI and CAH. Design and Patients A prospective, cross-sectional study including 74 PAI and 38 CAH patients. BMD was evaluated by DXA. Serum levels of bone turnover markers, minerals, vitamins and hormones, and urinary crosslinks were measured. Results Patients carrying the homozygous BclI polymorphism (GG) had significantly higher serum -CrossLaps (0 center dot 37 +/- 0 center dot 34g/l; P<0 center dot 05) and urinary collagen crosslinks (NTX, 68 center dot 1 +/- 32 center dot 4nmol/g; P<0 center dot 005) despite receiving the lowest average daily hydrocortisone dose of 9 center dot 9 +/- 3 center dot 7mg/m2 (P<0 center dot 05). The GG genotype occurred significantly more frequently in patients with increased NTX (OR=6 center dot 7, 95% CI=1 center dot 7825 center dot 38) than in patients with normal NTX. However, BMD was not significantly different between different allelic variants. No significant differences in associations of the genotypes with outcomes (or in clinical characteristics) were found between the sexes. Conclusions Although the sample sizes were relatively small and the results should be interpreted with caution, this study suggests that the homozygous (GG) genotype may be associated with higher bone resorption in adult PAI and CAH patients. GG-carriers needed a lower hydrocortisone dose on average supporting the concept that this GR variant is associated with increased cortisol sensitivity.
引用
收藏
页码:831 / 837
页数:7
相关论文
共 50 条
  • [31] Glucocorticoid receptor gene polymorphism and juvenile idiopathic arthritis
    Kostik, M. M.
    Klyushina, A. A.
    Moskalenko, M. V.
    Scheplyagina, L. A.
    Larionova, V. I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 441 - 441
  • [32] Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
    R. A. M. Quax
    J. W. Koper
    A. M. Huisman
    A. Weel
    J. M. W. Hazes
    S. W. J. Lamberts
    R. A. Feelders
    Rheumatology International, 2015, 35 : 1325 - 1333
  • [33] Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
    Quax, R. A. M.
    Koper, J. W.
    Huisman, A. M.
    Weel, A.
    Hazes, J. M. W.
    Lamberts, S. W. J.
    Feelders, R. A.
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (08) : 1325 - 1333
  • [34] Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma
    Hammarstrand, Casper
    Ragnarsson, Oskar
    Hallen, Tobias
    Andersson, Eva
    Skoglund, Thomas
    Nilsson, Anna G.
    Johannsson, Gudmundur
    Olsson, Daniel S.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (03) : 251 - 256
  • [35] Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism
    Peacey, Steven R.
    Wright, Dianne
    Aye, Mo
    Moisey, Robert
    CLINICAL ENDOCRINOLOGY, 2012, 77 (01) : 94 - 98
  • [36] Bone changes and glucocorticoid replacement therapy doses in patients with primary adrenal insufficiency
    Vanuga, P.
    Payer, J.
    Pura, M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S310 - S310
  • [37] The glucocorticoid receptor gene as a candidate for gene therapy in asthma
    M Mathieu
    C Gougat
    D Jaffuel
    M Danielsen
    P Godard
    J Bousquet
    P Demoly
    Gene Therapy, 1999, 6 : 245 - 252
  • [38] BcII polymorphism in the glucocorticoid receptor gene in patients with Graves ophthalmopathy treated with glucocorticoids
    Beleslin, B.
    Antic, J.
    Trbojevic, B.
    Zarkovic, M.
    Ciric, J.
    Stojkovic, M.
    Savic, S.
    Damjanovic, S.
    HORMONE RESEARCH, 2007, 68 : 76 - 76
  • [39] The glucocorticoid receptor gene as a candidate for gene therapy in asthma
    Mathieu, M
    Gougat, C
    Jaffuel, D
    Danielsen, M
    Godard, P
    Bousquet, J
    Demoly, P
    GENE THERAPY, 1999, 6 (02) : 245 - 252
  • [40] Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis
    Melief, Jeroen
    Koper, Jan W.
    Endert, Erik
    Moller, Holger J.
    Hamann, Jorg
    Uitdehaag, Bernard M.
    Huitinga, Inge
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 299 : 84 - 89